Chiron's Pulminiq -- a treatment for preventing lung transplant rejection -- has received a split decision by an influential FDA advisory panel. The panel voted 8-8 on Pulminiq after staffers had questioned the accuracy of data drawn from a small clinical trial. The trial found a 79 percent reduction in the risk of death among the 26 patients using the drug. Some members of the panel wondered if other factors could have influenced the data. The drug is only a small one for Chiron, though, with an estimated market value of $40 million to $75 million. The FDA will now take up the issue and decide by July 14.
- read this article from the San Francisco Chronicle